467 results match your criteria: "Institute of Clinical Neuroimmunology[Affiliation]"
Proc Natl Acad Sci U S A
March 2023
Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, 82152 Planegg-Martinsried, Germany.
Nat Biotechnol
November 2023
Division of Clinical Pharmacology, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid leukemia (AML) due to a lack of safe targets. Here we leveraged an atlas of publicly available RNA-sequencing data of over 500,000 single cells from 15 individuals with AML and tissue from 9 healthy individuals for prediction of target antigens that are expressed on malignant cells but lacking on healthy cells, including T cells. Aided by this high-resolution, single-cell expression approach, we computationally identify colony-stimulating factor 1 receptor and cluster of differentiation 86 as targets for CAR-T cell therapy in AML.
View Article and Find Full Text PDFFront Neurol
February 2023
Department of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
J Neuroinflammation
March 2023
Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistr.15, 81377, Munich, Germany.
Objectives: Reactive gliosis is a common pathological hallmark of CNS pathology resulting from neurodegeneration and neuroinflammation. In this study we investigate the capability of a novel monoamine oxidase B (MAO-B) PET ligand to monitor reactive astrogliosis in a transgenic mouse model of Alzheimer`s disease (AD). Furthermore, we performed a pilot study in patients with a range of neurodegenerative and neuroinflammatory conditions.
View Article and Find Full Text PDFJ Clin Med
March 2023
Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, 81377 Munich, Germany.
It remains unresolved whether central nervous system involvement in treated classical galactosemia (CG) is a progressive neurodegenerative process. This study aimed to investigate retinal neuroaxonal degeneration in CG as a surrogate of brain pathology. Global peripapillary retinal nerve fibre layer (GpRNFL) and combined ganglion cell and inner plexiform layer (GCIPL) were analysed in 11 CG patients and 60 controls (HC) using spectral-domain optical coherence tomography.
View Article and Find Full Text PDFBrain
April 2023
Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Neurol Neuroimmunol Neuroinflamm
May 2023
From the Institute of Clinical Neuroimmunology (M.B., K.E., E.B., S.W., S.M., A.T., A.F.-H., T.K., M.K., E.M., F.S.T.), University Hospital, Ludwig-Maximilians-Universität Munich; Biomedical Center (BMC) (M.B., K.E., E.B., S.W., S.M., A.T., A.F.-H., T.K., M.K., E.M., F.S.T.), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried; Graduate School of Systemic Neurosciences Ludwig-Maximilians-Universität Munich (M.B., K.E.); Munich Cluster for Systems Neurology (SyNergy) (E.B., M.K., F.S.T.); Innate Immunity Unit (A.T.), Institut Pasteur, Inserm U1223, Paris, France; Université de Paris (A.T.), Sorbonne Paris Cité, France; Institute of Laboratory Medicine (P.E.), University Hospital, LMU Munich; Institute of Clinical and Molecular Virology (P.S.), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg; and Department of Neurology (J.L.), University Hospital Ulm, Germany.
Background And Objectives: Antibodies (Abs) against the cytoplasmic protein glutamic acid decarboxylase 65 (GAD65) are detected in patients with neurologic syndromes together referred to as GAD65-Ab spectrum disorders. The response of some of these patients to plasma exchange or immunoglobulins indicates that GAD65-Abs could contribute to disease pathogenesis at least at some stages of disease. However, the involvement of GAD65-reactive B cells in the CNS is incompletely understood.
View Article and Find Full Text PDFJ Neurol Neurosurg Psychiatry
July 2023
Moorfield's Eye Hospital, The National Hospital for Neurology and Neurosurgery, Queen Square Institute of Neurology, University College London, London, UK.
Mult Scler
June 2023
Department of Neurology, Hannover Medical School, Hannover, Germany.
Background: There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD).
Objective: To assess cognitive performance and changes over time in NMOSD.
Methods: This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients.
Mult Scler
May 2023
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Background: Data on the humoral vaccine response in patients on anti-interleukin-6 (IL-6) receptor therapy remain scarce.
Objective: The main objective of our study was to investigate the humoral response after vaccination against SARS-CoV-2 in neuromyelitis optica spectrum disorder (NMOSD)/myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) patients treated with anti-IL-6 receptor therapy. Secondarily, we analyzed relapse activity timely associated with vaccination.
Neurol Neuroimmunol Neuroinflamm
March 2023
From the Institute of Clinical Neuroimmunology (S.H., E.O., H.K.W., A.V., I.M., F.T., T.K., E.M., S.M.), Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität München; Graduate School of Systemic Neurosciences (S.H.), Ludwig-Maximilians-Universität München, Germany; Department of Neurology (A.V.), Koc University School of Medicine; Department of Neuroscience (V.Y., E.T.), Aziz Sancar Institute of Experimental Medicine, Istanbul University; Department of Neurology (R.T.), Haydarpasa Numune Education and Research Hospital, Istanbul, Türkiye; Core Facility Bioinformatics (T.S.), Biomedical Center, Ludwig-Maximilians-Universität München, Germany; Munich Cluster for Systems Neurology (SyNergy) (F.T.), Germany.
Acta Neuropathol
March 2023
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
B cells contribute to the pathogenesis of both cellular- and humoral-mediated central nervous system (CNS) inflammatory diseases through a variety of mechanisms. In such conditions, B cells may enter the CNS parenchyma and contribute to local tissue destruction. It remains unexplored, however, how infection and autoimmunity drive transcriptional phenotypes, repertoire features, and antibody functionality.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
March 2023
From the Department of Neurology (M.W.H., F.B., D.T., S.G., C.T.), Hannover Medical School, Germany; Department of Neurology (I.A., T.P., K.H., I.K.), St. Josef Hospital, Ruhr University Bochum, Germany; Department of Neurology (L.K.), University of Münster, Germany; Department of Neurology and Institute of Neuroimmunology and MS (INIMS) (V.H., J.-P.S.), University Medical Center Hamburg-Eppendorf, Germany; Aix-Marseille Univ (J.-P.S.), CNRS, CRMBM, UMR 7339, Marseille Cedex, France; APHM (J.-P.S.), Hopital de La Timone, CEMEREM, Marseille, France; Department of Neurology (C.W., Y.G.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Department of Neurology (T.E.), Kliniken Südostbayern-Klinikum Traunstein, Germany; Department of Neurology (F.L.), University Medical Center of the Johannes Gutenberg University Mainz, Germany; Hannover Medical School (P.B.), Department of Diagnostic and Interventional Neuroradiology, Germany; Department of Neurology (A.-S.L.), German Diagnostic Clinic, DKD Helios Clinic Wiesbaden, Germany; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany; Department of Neurology (P.S.R.), Medical University of Vienna, Austria; Experimental and Clinical Research Center (F.P., J.B.-S., A.D.), a Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Germany; Department of Neurology (F.P., J.B.-S., A.D.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Germany; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) (F.P., J.B.-S., A.D.), Berlin, Germany; Department of Neurology (F.T.B.), University of Leipzig, Germany; Department of Neurology (R.P.), University of Essen, Germany; Department of Neurology (A.W.), Herford Hospital, Germany; Institute of Clinical Neuroimmunology (H.P., T.K.), LMU Hospital, Ludwig-Maximilians Universität München, Germany; Department of Neurology (M.P., M.K.), Alfried-Krupp-Krankenhaus Essen, Germany; Department of Neurology (M.K., P.A., O.A., M.R.), Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf, Germany; Department of Neurology (M.S.), University of Ulm, Germany; Department of Neurology (K.G., A.B.), School of Medicine, Technical University Munich, Klinikum Rechts der Isar, Germany; and Molecular Neuroimmunology Group (S.J., B.W.), Department of Neurology, University of Heidelberg, Germany.
Background And Objectives: To evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated diseases (MOGAD).
Methods: This multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire.
Cell Rep Med
February 2023
Department of Neurology with Institute of Translational Neurology, University Hospital Münster, WWU, Münster 48149, Germany. Electronic address:
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we use a systems-level approach combined with high-dimensional characterization of Ab-associated immune features to deeply profile humoral immune responses in 123 patients with MOGAD.
View Article and Find Full Text PDFJ Neurol Sci
February 2023
Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Str. 62, Cologne 50937, Germany.
EMBO Mol Med
February 2023
Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Functional recovery following incomplete spinal cord injury (SCI) depends on the rewiring of motor circuits during which supraspinal connections form new contacts onto spinal relay neurons. We have recently identified a critical role of the presynaptic organizer FGF22 for the formation of new synapses in the remodeling spinal cord. Here, we now explore whether and how targeted overexpression of FGF22 can be used to mitigate the severe functional consequences of SCI.
View Article and Find Full Text PDFJ Exp Med
March 2023
Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Functional recovery after incomplete spinal cord injury depends on the effective rewiring of neuronal circuits. Here, we show that selective chemogenetic activation of either corticospinal projection neurons or intraspinal relay neurons alone led to anatomically restricted plasticity and little functional recovery. In contrast, coordinated stimulation of both supraspinal centers and spinal relay stations resulted in marked and circuit-specific enhancement of neuronal rewiring, shortened EMG latencies, and improved locomotor recovery.
View Article and Find Full Text PDFElife
December 2022
Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany.
Neuroinflammation after stroke is characterized by the activation of resident microglia and the invasion of circulating leukocytes into the brain. Although lymphocytes infiltrate the brain in small number, they have been consistently demonstrated to be the most potent leukocyte subpopulation contributing to secondary inflammatory brain injury. However, the exact mechanism of how this minimal number of lymphocytes can profoundly affect stroke outcome is still largely elusive.
View Article and Find Full Text PDFNeural Regen Res
June 2023
Munich Cluster of Systems Neurology (SyNergy); Institute of Clinical Neuroimmunology, Biomedical Building and Clinic of the Ludwig-Maximilians Universität München, Munich, Germany.
Nat Neurosci
December 2022
Biomedical Center Munich (BMC), Department of Cell Biology and Anatomy, Medical Faculty, LMU, Munich, Germany.
Decreasing the activation of pathology-activated microglia is crucial to prevent chronic inflammation and tissue scarring. In this study, we used a stab wound injury model in zebrafish and identified an injury-induced microglial state characterized by the accumulation of lipid droplets and TAR DNA-binding protein of 43 kDa (TDP-43) condensates. Granulin-mediated clearance of both lipid droplets and TDP-43 condensates was necessary and sufficient to promote the return of microglia back to the basal state and achieve scarless regeneration.
View Article and Find Full Text PDFBrain
May 2023
Department of Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany.
Autoimmune neuropathy associated with antibodies against pan-neurofascin is a new subtype of nodo-paranodopathy. It is relevant because it is associated with high morbidity and mortality. Affected patients often require intensive care unit treatment for several months, and data on the reversibility and long-term prognosis are limited.
View Article and Find Full Text PDFEur J Neurol
February 2023
Institute for Neuroradiology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Background And Purpose: Brain pseudoatrophy has been shown to play a pivotal role in the interpretation of brain atrophy measures during the first year of disease-modifying therapy in multiple sclerosis. Whether pseudoatrophy also affects the spinal cord remains unclear. The aim of this study was to analyze the extent of pseudoatrophy in the upper spinal cord during the first 2 years after therapy initiation and compare this to the brain.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
November 2022
From the Hans-Berger Department of Neurology (T.K., C.G., Albrecht Kunze), University Hospital Jena; Department of Neurology (Marie Madlener, Michael Malter), Faculty of Medicine and University Hospital Cologne, University of Cologne; Department of Neurology (K.A.), University of Regensburg; Department of Epileptology (Krankenhaus Mara) (C.G.B.), Bielefeld University, Medical School, Campus Bielefeld-Bethel; Department of Psychiatry and Psychotherapy (Y.B.), Asklepios Hospital Teupitz; Department of Neurology (K.D.), University of Würzburg; Department of Neurology (A.F.), Hospital Lüneburg; Department of Neurology (S.T.G.), University Hospital Erlangen; Department of Neurology (G.R.), Klinikum Dortmund; Department of Neuro-pediatrics (M.H.), RWTH University Hospital Aachen; Department of Neurology (R.H.), Carl-Thiem Klinikum Cottbus; Department of Neurology (K.H.), University of Bochum; Institut für Neuroimmunologie und Multiple Sklerose (M.K.), Zentrum für Molekulare Neurobiologie Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Department of Neurology (C.K.), Klinikum Osnabrück; Department of Neurology (P.K.), University of Magdeburg; Department of Neurology (Andrea Kraft), Martha-Maria Hospital Halle; Department of Neurology (J.L.), University of Ulm; Department of Neurology (T.M., M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Germany; Department of Neurology (A.P.), Klinikum Hirslanden, Zürich; Department of Neurology (F.v.P., M.S.), University of Greifswald; Department of Neurology and Experimental Neurology (H.P.), Charité Berlin, and German Center for Neurodegenerative Diseases (DZNE); Department of Neurology (S.R., N.M.), University of Freiburg; Department of Neurology (M.R.), Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany; Department of Neuropediatrics (K.R.), Vestische Kinder-und Jugendklinik Datteln; Department of Neurology (I.S.), University Hospital Giessen and Marburg, Giessen; Department of Neurology (J.S.), Asklepios Hospital Nord, Hamburg; Department of Neurology (P.S.), Hospital Hubertusburg, Wermsdorf; Department of Neurology (K.-W.S.), University Hospital Hannover; Department of Epileptology (R.S.), University Hospital Bonn; Department of Neurology (S.C.T.), RWTH University Hospital Aachen; Institute of Clinical Neuroimmunology (F.T.), University Hospital, Ludwig-Maximilians-Universität Munich, Germany and Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried, Germany; Department of Neurology (F.T.B.), University of Leipzig; Department of Neurology (C.U.), Hospital Ludwigshafen; Institute of Clinical Chemistry (K.-P.W.), University Hospital Schleswig-Holstein, Kiel/Lübeck, Germany; Department of Neurology (B.W.), University of Heidelberg; Department of Neurology (S.M.), University Hospital, Technische Universität Dresden; Universitätsklinikum Knappschaftskrankenhaus Bochum Langendreer (S.M.), Klinik für Neurologie; Department of Neurology (U.Z.), University of Rostock; Department of Neurology (F.L.), Christian-Albrechts-University Kiel; Department of Neurology with Institute of Translational Neurology (N.M.), University Hospital Muenster; and Department of Neurology (Albrecht Kunze), Zentralklinik Bad Berka, Germany.
Front Neurol
September 2022
Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
To pave the way for healthy aging in early treated phenylketonuria (ETPKU) patients, a better understanding of the neurological course in this population is needed, requiring easy accessible biomarkers to monitor neurological disease progression in large cohorts. The objective of this pilot study was to investigate the potential of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as blood biomarkers to indicate changes of the central nervous system in ETPKU. In this single-center cross-sectional study, GFAP and NfL concentrations in serum were quantified using the Simoa multiplex technology in 56 ETPKU patients aged 6-36 years and 16 age matched healthy controls.
View Article and Find Full Text PDF